Murine Irritation & Redness Relief (Naphazoline Hydrochloride)

Naphazoline Hydrochloride, the active ingredient in Murine Relief, is an alpha‑adrenergic agonist presented as an ocular solution for topical eye use. It reduces ocular redness and irritation by constricting conjunctival blood vessels and is available over‑the‑counter in the EU market.

GNH USA supplies Murine Relief as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naphazoline Hydrochloride is an ocular decongestant that alleviates redness by acting on conjunctival blood vessels.

- Ocular redness: diminishes visible redness through vasoconstriction of conjunctival vessels. - Eye irritation: relieves mild discomfort and burning associated with irritants. - Conjunctival hyperemia: reduces excessive blood flow causing a red eye appearance.

Common side effects are generally mild and transient.

Common Side Effects: - Stinging or burning sensation at the application site. - Temporary blurred vision. - Dryness of the ocular surface. - Mild eye irritation. - Slight headache. - Transient increase in intra‑ocular pressure.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Corneal ulcer or keratitis. - Persistent hypertension or tachycardia. - Rebound hyperemia after prolonged use. - Vision loss. - Systemic sympathomimetic effects in susceptible individuals.

Before using Murine Relief, consider the following safety measures.

- Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown safety; weigh benefits against potential risks. - Contact lens wearers: avoid use while lenses are in place. - Prolonged use: may cause rebound redness (hyperemia). - Glaucoma patients: use with caution and under medical supervision. - Store at room temperature: keep in original container, protect from light and moisture.

Naphazoline Hydrochloride may interact with other sympathomimetic agents.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: additive vasoconstrictive effect. - Other topical ocular decongestants: may increase systemic exposure.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: monitor blood pressure and heart rate. - Systemic antihypertensives: possible reduction in antihypertensive efficacy. - Anticholinergic eye drops: may enhance ocular dryness.